← All trials
NCT06429449
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2024
- Primary completion
- Dec 31, 2026
- Completion date
- Nov 30, 2027
- First posted
- May 28, 2024
- Last posted
- Aug 15, 2024
- Enrollment
- 30
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Colorado, DenverLead sponsor
- The Leukemia and Lymphoma SocietyCollaborator
- University of Colorado, DenverOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.